USA - NASDAQ:XENE - CA98420N1050 - Common Stock
Overall XENE gets a fundamental rating of 3 out of 10. We evaluated XENE against 536 industry peers in the Biotechnology industry. XENE has a great financial health rating, but its profitability evaluates not so good. XENE does not seem to be growing, but still is valued expensively.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -41.26% | ||
ROE | -43.89% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Altman-Z | 42.11 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 15.14 | ||
Quick Ratio | 15.14 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
39.61
+0.41 (+1.05%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 407.24 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 4.82 | ||
P/tB | 4.82 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -41.26% | ||
ROE | -43.89% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 60.66% | ||
Cap/Sales | 20.97% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 15.14 | ||
Quick Ratio | 15.14 | ||
Altman-Z | 42.11 |